<DOC>
	<DOCNO>NCT01294085</DOCNO>
	<brief_summary>To assess difference prognosis unresectable recurrent biliary tract cancer evaluate prognostic factor .</brief_summary>
	<brief_title>Case Series Study Biliary Tract Cancer Patients Japan</brief_title>
	<detailed_description>Most patient biliary tract cancer advance disease diagnosis often relapse despite surgery . Combination therapy gemcitabine cisplatin could standard therapy kind cancer evidence phase III study compare gemcitabine alone . However prognosis tolerability chemotherapy patient recurrent biliary tract cancer radical resection might differ unresectable biliary tract cancer , dose intensity chemotherapy influence adjuvant chemotherapy and/or hepatic resection .</detailed_description>
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<criteria>Unresectable recurrent biliary tract cancer</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>